B-cell lineage neoplasms transdifferentiating into histiocytic/dendritic cell neoplasms: diversity, differentiation lineage, genomic alterations, and therapy: Report from the 2021 SH/EAHP Workshop.
Wenbin XiaoCatalina AmadorJames R CookMagdalena CzaderSandeep DaveAhmet DoganAmy DuffieldMariusz A WasikReza NejatiGerman OttMariusz WasikPublished in: American journal of clinical pathology (2023)
Transdifferentiated HDCNs demonstrate heterogeneity and pose diagnostic challenges with regard to exact classification, but the in-depth characterization of the submitted cases have added to our understanding of the secondary HDCNs transdifferentiated from B-cell lymphoma/leukemia. Continuous efforts focusing on deciphering the specific cell lineage and differentiation state of these tumors will be critical for their accurate classification. Comprehensive molecular characterization of HDCNs may be informative in this regard. With the list of novel pharmacologic inhibitors of the MAPK pathway continuing to expand, improved outcomes for HDCN can be expected.
Keyphrases
- single cell
- dendritic cells
- deep learning
- machine learning
- oxidative stress
- cell therapy
- regulatory t cells
- cell fate
- signaling pathway
- immune response
- type diabetes
- high resolution
- diffuse large b cell lymphoma
- quality improvement
- dna methylation
- density functional theory
- skeletal muscle
- smoking cessation
- medical education
- glycemic control